Skip to main content

Advertisement

SpringerLink
Log in

Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

The purpose of this study is to analyze treatment persistence in patients with osteoporosis after fracture diagnosis in German primary care practices. We found that pain increased treatment persistence. One key next step is to demonstrate whether or not this pain is related to fracture.

Introduction

To analyze treatment persistence in patients with osteoporosis after fracture diagnosis in German primary care practices.

Methods

This study included postmenopausal women with osteoporosis aged between 40 and 90 years from 1188 general and 175 orthopedist practices in Germany. Treatment started between 2004 and 2013. The primary outcome measure was treatment persistence within 12 months after therapy initiation. Discontinuation of treatment was defined as a period of at least 90 days without therapy. Persistence analyses were carried out using Kaplan-Meier curves and log-rank tests, and the analyses of the impact of fracture on discontinuation risk were based on Cox regression models (with and without adjustment for pain medications).

Results

Thirteen thousand nine hundred seventy-five subjects (mean age = 74.8 years) were included in the group with fracture before therapy initiation and 18,138 (mean age = 72.7 years) in the group without fracture. Within 12 months after treatment initiation, therapy persistence increased with the delay between osteoporosis diagnosis and therapy initiation, rising from 40.7 % when the delay was lower than or equal to 12 months to 44.3 % when it exceeded 36 months (p value <0.0001). Fracture only decreased the risk of treatment discontinuation when the model was not adjusted for pain medications (HR = 0.95, 95 % CI 0.93–0.98, p value <0.0001).

Conclusions

Pain increased treatment persistence in women with osteoporosis and fracture. Further studies are needed to better understand factors influencing persistence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. International Osteoporosis Foundation (2015) Facts and statistics. Accessed on 08/15/15

  2. Hadji P, Klein S, Gothe H, Häussler B, Kless T, Schmidt T, Steinle T, Verheyen F, Linder R (2013) The epidemiology of osteoporosis—Bone Evaluation Study (BEST): an analysis of routine health insurance data. Dtsch Ärztebl Int 110:52–57. doi:10.3238/arztebl.2013.0052

    PubMed  PubMed Central  Google Scholar 

  3. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. doi:10.1007/s11657-013-0136-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Salari Sharif P, Abdollahi M, Larijani B (2011) Current, new and future treatments of osteoporosis. Rheumatol Int 31:289–300. doi:10.1007/s00296-010-1586-z

    Article  CAS  PubMed  Google Scholar 

  5. Hodsman A, Papaioannou A, Cranney A (2006) Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis. Can Med Assoc J 175:48. doi:10.1503/cmaj.060624

    Article  Google Scholar 

  6. Whitaker M, Guo J, Kehoe T, Benson G (2012) Bisphosphonates for osteoporosis—where do we go from here? N Engl J Med 366:2048–2051. doi:10.1056/NEJMp1202619

    Article  CAS  PubMed  Google Scholar 

  7. Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD (2004) Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34:736–746. doi:10.1016/j.bone.2003.12.013

    Article  CAS  PubMed  Google Scholar 

  8. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352

    Article  CAS  PubMed  Google Scholar 

  9. Bone HG, Hosking D, Devogelaer J-P, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC et al (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199. doi:10.1056/NEJMoa030897

    Article  CAS  PubMed  Google Scholar 

  10. Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. doi:10.1002/14651858.CD004523.pub3

    Google Scholar 

  11. Kennel KA, Drake MT (2009) Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc 84:632–638

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176

    Article  CAS  PubMed  Google Scholar 

  13. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA, AMG 162 Bone Loss Study Group (2007) Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res Off J Am Soc Bone Miner Res 22:1832–1841. doi:10.1359/jbmr.070809

    Article  CAS  Google Scholar 

  14. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765. doi:10.1056/NEJMoa0809493

    Article  CAS  PubMed  Google Scholar 

  15. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441. doi:10.1056/NEJM200105103441904

    Article  CAS  PubMed  Google Scholar 

  16. Orwoll E, Scheele W, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman J-M, Clancy A, Gaich G (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17. doi:10.1359/jbmr.2003.18.1.9

    Article  CAS  PubMed  Google Scholar 

  17. Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T (2011) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 23:223–231. doi:10.1007/s00198-011-1535-z

    Article  PubMed  Google Scholar 

  18. Ziller V, Zimmermann SP, Kalder M, Ziller M, Seker-Pektas B, Hellmeyer L, Hadji P (2010) Adherence and persistence in patients with severe osteoporosis treated with teriparatide. Curr Med Res Opin 26:675–681. doi:10.1185/03007990903538409

    Article  CAS  PubMed  Google Scholar 

  19. Hadji P, Papaioannou N, Gielen E, Tepie MF, Zhang E, Frieling I, Geusens P, Makras P, Resch H, Möller G et al (2015) Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int. doi:10.1007/s00198-015-3164-4

    PubMed Central  Google Scholar 

  20. Patel U, Skingle S, Campbell GA, Crisp AJ, Boyle IT (1991) Clinical profile of acute vertebral compression fractures in osteoporosis. Br J Rheumatol 30:418–421

    Article  CAS  PubMed  Google Scholar 

  21. Silverman SL (1992) The clinical consequences of vertebral compression fracture. Bone 13(Suppl 2):S27–S31

    Article  PubMed  Google Scholar 

  22. Becher H, Kostev K, Schröder-Bernhardi D (2009) Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 47:617–626

    Article  CAS  PubMed  Google Scholar 

  23. Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmer-Shevlin N (1993) Medication compliance: a healthcare problem. Ann Pharmacother 27:S1–S24

    CAS  PubMed  Google Scholar 

  24. Miller NH (1997) Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 102:43–49

    Article  CAS  PubMed  Google Scholar 

  25. Tosteson ANA, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209–216

    Article  PubMed  Google Scholar 

  26. Segal E, Tamir A, Ish-Shalom S (2003) Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 5:859–862

    PubMed  Google Scholar 

  27. Turbí C, Herrero-Beaumont G, Acebes JC, Torrijos A, Graña J, Miguélez R, Sacristán J, Marín F (2004) Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 26:245–256. doi:10.1016/S0149-2918(04)90023-9

    Article  PubMed  Google Scholar 

  28. Hadji P, Felsenberg D, Amling M, Hofbauer LC, Kandenwein JA, Kurth A (2014) The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 25:339–347. doi:10.1007/s00198-013-2515-2

    Article  CAS  Google Scholar 

  29. Papaioannou A, Khan A, Belanger A, Bensen W, Kendler D, Theoret F, Amin M, Brekke L, Erdmann M, Walker V et al (2015) Persistence with denosumab therapy among osteoporotic women in the Canadian patient-support program. Curr Med Res Opin 31:1391–1401. doi:10.1185/03007995.2015.1053049

    Article  CAS  PubMed  Google Scholar 

  30. Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Ström O (2015) Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. doi:10.1007/s00198-015-3253-4

    Google Scholar 

  31. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637–645. doi:10.1001/jama.282.7.637

    Article  CAS  PubMed  Google Scholar 

  32. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022. doi:10.4065/81.8.1013

    Article  PubMed  Google Scholar 

  33. Rossini M, Bianchi G, Munno OD, Giannini S, Minisola S, Sinigaglia L, Adami S (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914–921. doi:10.1007/s00198-006-0073-6

    Article  CAS  PubMed  Google Scholar 

  34. Carr AJ, Thompson PW, Cooper C (2006) Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 17:1638–1644. doi:10.1007/s00198-006-0166-2

    Article  CAS  PubMed  Google Scholar 

  35. Carney RM, Freedland KE, Eisen SA, Rich MW, Jaffe AS (1995) Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol Off J Div Health Psychol Am Psychol Assoc 14:88–90

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biology, École Normale Supérieure de Lyon, Lyon, France

    L. Jacob

  2. Department of Gynecology and Obstetrics, Philipps-Universität Marburg, Marburg, Germany

    M. Dreher

  3. IMS Health Epidemiology, Darmstädter Landstraße 108, 60598, Frankfurt am Main, Germany

    K. Kostev

  4. Nordwest Hospital, Philipps-University of Marburg, Frankfurt, Germany

    P. Hadji

Authors
  1. L. Jacob
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Dreher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Kostev
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Hadji
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Kostev.

Ethics declarations

Conflicts of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jacob, L., Dreher, M., Kostev, K. et al. Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture. Osteoporos Int 27, 963–969 (2016). https://doi.org/10.1007/s00198-015-3378-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-015-3378-5

Keyword

Search

Navigation